Apitegromab for Obesity

(EMBRAZE Trial)

Recruiting at 6 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Scholar Rock, Inc.

Stay on Your Current Meds

Prior Safety Data

Trial Summary

What is the purpose of this trial?

A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity

Research Team

Eligibility Criteria

This trial is for adults who are overweight or obese. It's not specified, but typically participants should be in stable health and willing to follow the study procedures. Details on specific inclusion and exclusion criteria are not provided.

Inclusion Criteria

Able to comprehend the informed consent process and provide written informed consent prior to study enrollment and the conduct of any study-related assessments

I am between 18 and 65 years old.

My weight has been stable, within about 11 pounds, for the last 3 months.

Exclusion Criteria

I haven't had immunosuppressive, chemotherapy, or radiation treatments in the last year.

I have a history of or currently have heart, brain, blood vessel, lung, liver, pancreas, muscle, or mental health issues.

I have cancer that is not just skin cancer.

Treatment Details

Interventions

• Apitegromab (Monoclonal Antibodies)

Trial Overview The trial is testing apitegromab as an additional treatment alongside GLP-1 agonist therapy (like Tirzepatide or Semaglutide) compared to a placebo, to see if it helps with weight loss in overweight or obese individuals.

Participant Groups

Group I: Cohort 1 Experimental Treatment 3 Interventions

Apitegromab + incretin mimetic

Group II: Cohort 2 Placebo Group 3 Interventions

Placebo + incretin mimetic

Who Is Running the Clinical Trial?

Scholar Rock, Inc.

Lead Sponsor

Trials

7

Recruited

710+